Lineage Cell Therapeutics (LCTX) executive compensation, 2026 proxy

Brian M. Culley, Chief Executive Officer, was paid $2.1M in 2025, down 17% from $2.5M the year before.

Filed
April 29, 2026
Annual meeting
June 10, 2026
Pay year
2025
Named executives
3
CEO total pay
$2.1M-17% vs prior year
Prior say-on-pay support
96%of votes cast
CEO Target Bonus Percentage
60%Of annual base salary
NEO Target Bonus Percentage
40%For Ms. Howe and Mr. Samuel
Gross Capital Raising Proceeds
$26MRaised during fiscal year 2025
Total Shareholder Return
221%Achieved during year ended December 31, 2025

How Culley was paid

$2.1M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary33%Option awards42%Non-equity incentive25%All other compensation1%

Named executive officers

ExecutiveTotal
Brian M. CulleyChief Executive Officer$2,111,170
Jill A. HoweChief Financial Officer$1,005,925
George A. Samuel IIIGeneral Counsel and Corporate Secretary$978,225

What changed and why

  • $2.1MCEO Brian M. Culley received total compensation of $2,111,170 in 2025, representing a decrease from the prior year total of $2,534,450.
  • 96%Shareholders approved executive compensation at the prior annual meeting with approximately 96% support.
  • 125%The board and compensation committee determined an overall performance achievement level of 125% for 2025.
  • Performance bonuses were awarded based on program progress, capital raising, budget management, and shareholder value.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.